Corbus Completes Phase 1a Study of CRB-913 and Initiates Phase 1b Study
Corbus Pharmaceuticals announced the completion of the single ascending dose, or SAD, and multiple ascending dose, or MAD, Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study, with completion expected in summer 2026. CRB-913 is a small molecule CB1 inverse agonist targeting chronic obesity management. The Phase 1a study assessed the safety, tolerability, and pharmacokinetics of escalating once-daily doses of CRB-913. No serious treatment-emergent adverse events were reported in the SAD/MAD study. CRB-913 was not associated with GI intolerability. There were no reported cases of nausea, vomiting, or constipation and only a single case of mild diarrhea. Daily neuropsychiatric assessments remained stable and negative at all time points for all participants. No cases of suicidality, depression, or insomnia were reported in the study. The PK profile for CRB-913 was established and was found to be suitable for a once-daily oral dosing. In the dedicated obese MAD cohort, all CRB-913-treated participants, and none in the placebo group, experienced weight loss. The CRB-913-treated participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14. Individual participant weight loss ranged from 1.3% to 4.3%. Weight loss started early and deepened with time. Notably, several participants treated with CRB-913 reported reduction in food-related thoughts and cravings.
Trade with 70% Backtested Accuracy
Analyst Views on CRBP
About CRBP
About the author
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Corbus Shares Drop After Initial Results for Oral Obesity Treatment CRB-913
Corbus Pharmaceuticals Phase 1 Study Results: Corbus (CRBP) shares fell approximately 3% after reporting results from its phase 1 study of CRB-913, an oral treatment for chronic obesity, which included both single and multiple ascending dose cohorts.
Efficacy and Safety Findings: The multiple ascending dose cohort of obese patients experienced a mean placebo-adjusted weight loss of 2.9% by day 14, with the drug being well tolerated and no serious adverse events reported, although mild anxiety and irritability were noted in some patients.
Market Reaction and Financial Updates: Corbus's stock price dropped 17% following a $75 million fundraising effort priced at $13 per share, alongside a GAAP EPS loss of -$1.90, which missed expectations by $0.16.
Ongoing Developments: The company continues to focus on its drug development efforts, with discussions around data updates and insights from other studies, including those related to head and neck cancer.
Corbus Pharmaceuticals' CRB-913 Achieves 2.9% Weight Loss in Obese Patients
- Clinical Trial Success: Corbus has completed the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a studies of CRB-913, with all doses being safe and well-tolerated, and no serious adverse events reported, indicating a strong safety profile.
- Significant Weight Loss Effect: In the 150 mg cohort, all CRB-913-treated participants (n=9) achieved a mean weight loss of 2.9% by Day 14, while none in the placebo group (n=3) lost weight, highlighting the drug's potential in obesity management.
- Follow-up Research Plans: Corbus has initiated the 12-week Phase 1b CANYON-1 study, targeting 240 obese, non-diabetic participants, with completion expected in summer 2026, to further validate the efficacy of CRB-913.
- Broad Market Potential: As a peripherally restricted CB1 inverse agonist with reduced brain penetration, CRB-913 may offer a new treatment option for obesity, particularly when used in combination with existing therapies, presenting significant market opportunities.
Corbus Announces Encouraging Phase 1a Results for CRB-913 in Obesity, Shares Rise - Update
Phase 1a Study Results: Corbus Pharmaceuticals announced positive results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for chronic obesity management, showing safety, tolerability, and a placebo-adjusted mean weight loss of 2.9% in participants.
Upcoming Phase 1b Study: The encouraging Phase 1a results support the initiation of the CANYON-1 Phase 1b study, which will involve 240 obese, non-diabetic participants over 12 weeks to evaluate different dosing regimens.
Safety Profile: CRB-913 is designed to minimize brain penetration, addressing safety concerns associated with previous drugs in its class, and has shown to be significantly less brain-penetrant compared to competitors.
Broader Pipeline and Stock Performance: Corbus's pipeline includes other candidates like CRB-701 and CRB-601, while the company's stock has seen significant fluctuations, currently trading at $13.77, up 34.17%.
Corbus Pharma Set to Announce Phase 1a Results for CRB-913 in Obesity Today
CRB-913 Presentation: Corbus Pharmaceuticals will present results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity treatment, during a webcast on December 11, 2025.
Obesity Treatment Challenges: Obesity is a significant global health issue with few safe pharmacological options; previous CB1 inverse agonists were withdrawn due to neuropsychiatric side effects.
CRB-913's Safety Profile: CRB-913 is designed to be a second-generation CB1 inverse agonist with reduced brain penetration, showing a 15-fold lower brain penetration compared to monlunabant and a 50 times lower brain:plasma ratio than rimonabant.
Financial Status: As of September 30, 2025, Corbus had $104 million in cash and investments, with a recent public offering expected to extend its cash runway into 2028; the stock is currently trading at $11.82, up 15.20%.
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
- Retail Influence: Corbus Pharmaceuticals has 46% of its shares held by retail investors, indicating significant influence over management and strategic decisions, which could drive the company towards more public-interest-aligned directions.
- Institutional Participation: Institutional investors own 23% of the company, which brings credibility from professional investors but also raises the risk of a 'crowded trade' in a company lacking a growth history.
- Hedge Fund Role: Hedge funds hold 24% of the shares and may attempt to influence management to create short-term value, particularly driven by major shareholders like Cormorant Asset Management and OrbiMed Advisors.
- Insider Ownership: Insiders own less than 1% of the company, which may challenge other shareholders in holding management accountable for decisions, especially given the market capitalization of only $156 million.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Corbus Shares Drop After Initial Results for Oral Obesity Treatment CRB-913
Corbus Pharmaceuticals Phase 1 Study Results: Corbus (CRBP) shares fell approximately 3% after reporting results from its phase 1 study of CRB-913, an oral treatment for chronic obesity, which included both single and multiple ascending dose cohorts.
Efficacy and Safety Findings: The multiple ascending dose cohort of obese patients experienced a mean placebo-adjusted weight loss of 2.9% by day 14, with the drug being well tolerated and no serious adverse events reported, although mild anxiety and irritability were noted in some patients.
Market Reaction and Financial Updates: Corbus's stock price dropped 17% following a $75 million fundraising effort priced at $13 per share, alongside a GAAP EPS loss of -$1.90, which missed expectations by $0.16.
Ongoing Developments: The company continues to focus on its drug development efforts, with discussions around data updates and insights from other studies, including those related to head and neck cancer.
Corbus Pharmaceuticals' CRB-913 Achieves 2.9% Weight Loss in Obese Patients
- Clinical Trial Success: Corbus has completed the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a studies of CRB-913, with all doses being safe and well-tolerated, and no serious adverse events reported, indicating a strong safety profile.
- Significant Weight Loss Effect: In the 150 mg cohort, all CRB-913-treated participants (n=9) achieved a mean weight loss of 2.9% by Day 14, while none in the placebo group (n=3) lost weight, highlighting the drug's potential in obesity management.
- Follow-up Research Plans: Corbus has initiated the 12-week Phase 1b CANYON-1 study, targeting 240 obese, non-diabetic participants, with completion expected in summer 2026, to further validate the efficacy of CRB-913.
- Broad Market Potential: As a peripherally restricted CB1 inverse agonist with reduced brain penetration, CRB-913 may offer a new treatment option for obesity, particularly when used in combination with existing therapies, presenting significant market opportunities.
Corbus Announces Encouraging Phase 1a Results for CRB-913 in Obesity, Shares Rise - Update
Phase 1a Study Results: Corbus Pharmaceuticals announced positive results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for chronic obesity management, showing safety, tolerability, and a placebo-adjusted mean weight loss of 2.9% in participants.
Upcoming Phase 1b Study: The encouraging Phase 1a results support the initiation of the CANYON-1 Phase 1b study, which will involve 240 obese, non-diabetic participants over 12 weeks to evaluate different dosing regimens.
Safety Profile: CRB-913 is designed to minimize brain penetration, addressing safety concerns associated with previous drugs in its class, and has shown to be significantly less brain-penetrant compared to competitors.
Broader Pipeline and Stock Performance: Corbus's pipeline includes other candidates like CRB-701 and CRB-601, while the company's stock has seen significant fluctuations, currently trading at $13.77, up 34.17%.
Corbus Pharma Set to Announce Phase 1a Results for CRB-913 in Obesity Today
CRB-913 Presentation: Corbus Pharmaceuticals will present results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity treatment, during a webcast on December 11, 2025.
Obesity Treatment Challenges: Obesity is a significant global health issue with few safe pharmacological options; previous CB1 inverse agonists were withdrawn due to neuropsychiatric side effects.
CRB-913's Safety Profile: CRB-913 is designed to be a second-generation CB1 inverse agonist with reduced brain penetration, showing a 15-fold lower brain penetration compared to monlunabant and a 50 times lower brain:plasma ratio than rimonabant.
Financial Status: As of September 30, 2025, Corbus had $104 million in cash and investments, with a recent public offering expected to extend its cash runway into 2028; the stock is currently trading at $11.82, up 15.20%.
